Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.

Merck ditches vibostolimab and favezelimab following huge pivotal programmes.

Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.

Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.

But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.

Menin, BTK and a Car-T skirmish featured over the ASH weekend.